Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 125 results
A DNA editing tool on a lab table with scientific books in the background.

Apr 28, 2026

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

Lilly has announced a significant partnership with AI-driven Profluent Bio, aiming to advance genetic medicine through a deal potentially worth up to $2.25 billion. The collaboration focuses on developing innovative DNA editing tools to address genetic conditions that currently lack effective treatments.The partnership will leverage Profluent's AI models to create site-specific recombinases—enzymes capable of precise DNA manipulation. Lilly will have exclusive rights to license and advance selec
A close-up of a DNA strand on a lab bench in a biotechnology lab.

Apr 28, 2026

AI start-up Profluent nabs Lilly as first big pharma partner

AI start-up Profluent has formed a significant partnership with Eli Lilly, valued at up to $2.25 billion, to advance gene-editing therapies. Founded in 2022, Profluent has garnered attention for its innovative technology that enables the insertion of entire genes into DNA, surpassing the localized editing capabilities of methods like CRISPR/Cas9. This collaboration aims to leverage Profluent's AI models for developing recombinase editors that can insert extensive DNA sequences at specific genomi
A minimalist representation of a genome sequence in a dark color scheme.

Apr 28, 2026

Europe AI in Genomics Market Size, Share, & Growth, 2034

The European AI in Genomics market is rapidly expanding, projected to grow from $448.48 million in 2025 to an impressive $9,568.11 million by 2034, with a remarkable compound annual growth rate (CAGR) of 40.5% from 2026 to 2034.This growth is driven by the integration of artificial intelligence technologies, such as machine learning and natural language processing, into genomics. These technologies are essential for analyzing the vast amounts of data generated by next-generation sequencing, faci
A minimalist representation of a single cell with surrounding data points.

Apr 27, 2026

AI in single-cell analysis: solving the interpretation gap

AI is increasingly becoming a key player in single-cell analysis, particularly in addressing the challenges of data interpretation in drug discovery.Single-cell omics is revolutionizing drug discovery by allowing researchers to analyze biological systems at an unprecedented resolution. However, the growing complexity of the data presents significant interpretative challenges. Parashar Dhapola, co-founder of Nygen Analytics, emphasizes that converting vast amounts of raw single-cell data into act
A flat illustration of a DNA strand

Apr 26, 2026

Did DRAGEN v4.5’s AI Genomics Push Just Shift Illumina’s (ILMN) Investment Narrative?

Illumina's recent release of DRAGEN v4.5 marks a significant advancement in genomic analysis, integrating enhanced accuracy and machine-learning capabilities into its software platform. This upgrade not only supports oncology applications but also strengthens multiomic analysis, including oncovirus detection, positioning Illumina as a key player in large-scale clinical genomics.The partnership with the Center for Data-Driven Discovery in Biomedicine aims to process 100,000 pediatric whole genome